IP Library Granted Patent US 8,501,753
Granted Patent B2
US 8,501,753 · App. 13/258,497 · Granted Aug 6, 2013

Useful pharmaceutical salts of 7-[(3R, 4R)-3-Hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3, 5-dihydro-pyrrolo [3, 2-D] pyrimidin-4-one

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,501,753
App. No.
13/258,497
Granted
Aug 6, 2013
Kind
B2
Abstract

The present disclosure provides novel hemi- and mono-salts of 7-[(3R,4R)-3-Hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3,5-dihydro-pyrrolo[3,2- d ]pyrimidin-4-one (Compound 1) with various organic and inorganic acids. In one embodiment, the organic acid is a C4 organic diacids. The present disclosure further provides novel methods for preparing these salts. The novel monohydrates hemisalts of the C4 organic diacids are isostructural and can be prepared with different properties. Multiple acids can be used simultaneously and the proportion of acids can be varied offering the opportunity to select hemi-salts of compound 1 with desired properties.

Claims (6)

1. A salt of compound 1:

wherein the salt of compound 1 is a hemi salt with a C 4 organic diacid, the C4 organic diacid being selected from the group consisting of succinic, fumaric, L-malic or a mixture thereof wherein the salt exhibits no polypmorphic variants or a reduced number of polymorphic variants.

2. The salt according to claim 1 , wherein the C 4 organic diacid is selected from the group consisting of succinic, fumaric, and L-malic acids.

3. The salt according to claim 1 , wherein the salt is a mixed salt.

4. The salt according to claim 3 , wherein the salt is selected from the group consisting of hemi(hemisuccinate, hemifumarate) monohydrate, hemi(hemisuccinate, hemimalate) monohydrate, and hemi(hemifumarate, hemimalate) monohydrate.

5. The salt according to claim 1 , wherein the salt is the hemisuccinate monohydrate.

Assignments (6)
SECURITY INTEREST Recorded Jan 23, 2026
From: BIOCRYST PHARMACEUTICALS, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 074485/0651 →
RELEASE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Apr 18, 2023
From: ATHYRIUM OPPORTUNITIES III CO-INVEST 1 LP
To: BIOCRYST PHARMACEUTICALS, INC.
Reel/Frame 063362/0550 →
RELEASE OF SECURITY INTEREST Recorded Apr 6, 2023
From: MIDCAP FINANCIAL TRUST
To: BIOCRYST PHARMACEUTICALS, INC.; MDCP, LLC
Reel/Frame 063348/0762 →
SECURITY INTEREST Recorded Dec 17, 2020
From: BIOCRYST PHARMACEUTICALS, INC.
To: ATHYRIUM OPPORTUNITIES III CO-INVEST 1 LP
Reel/Frame 054800/0634 →
RELEASE OF SECURITY INTEREST Recorded Dec 16, 2020
From: MIDCAP FINANCIAL TRUST, AS AGENT
To: BIOCRYST PHARMACEUTICALS, INC.; MDCP, LLC
Reel/Frame 054774/0446 →
SECURITY INTEREST Recorded Sep 26, 2016
From: BIOCRYST PHARMACEUTICALS, INC.; MDCP, LLC
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 039858/0967 →